ISA104
Chronic Hepatitis B Virus Infection
Phase 1/2aActive
Key Facts
About ISA Pharmaceuticals
ISA Pharmaceuticals is a clinical-stage biotech leveraging its proprietary synthetic long peptide (SLP) platform to create immunotherapies targeting cancers and persistent viral infections. The company's lead programs focus on HPV-related cancers and a therapeutic vaccine for chronic hepatitis B. While still pre-revenue, ISA has established key partnerships with major pharmaceutical companies to advance its pipeline and validate its platform technology.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Virus Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| DCR-HBVS | Dicerna Pharmaceuticals | Preclinical |
| ALN-HBV02 (VIR-2218) | Alnylam Pharmaceuticals | Phase 2 |